Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to compare the effectiveness of trastuzumab alone and in combination
with docetaxel in treating patients who have metastatic prostate cancer that is refractory to
hormone therapy.